171 related articles for article (PubMed ID: 35721186)
1. Design, Synthesis, and Antileukemic Evaluation of a Novel Mikanolide Derivative Through the Ras/Raf/MEK/ERK Pathway.
Rao Q; Xie K; Varier KM; Huang L; Song J; Yang J; Qiu J; Huang Y; Li Y; Gajendran B; Li Y; Liu S
Front Pharmacol; 2022; 13():809551. PubMed ID: 35721186
[TBL] [Abstract][Full Text] [Related]
2. Novel Mechanism by a Bis-Pyridinium Fullerene Derivative to Induce Apoptosis by Enhancing the MEK-ERK Pathway in a Reactive Oxygen Species-Independent Manner in BCR-ABL-Positive Chronic Myeloid Leukemia-Derived K562 Cells.
Sumi K; Tago K; Nakazawa Y; Takahashi K; Ohe T; Mashino T; Funakoshi-Tago M
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054935
[TBL] [Abstract][Full Text] [Related]
3. Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion.
Clark SS; Zhong L; Filiault D; Perman S; Ren Z; Gould M; Yang X
Clin Cancer Res; 2003 Oct; 9(12):4494-504. PubMed ID: 14555523
[TBL] [Abstract][Full Text] [Related]
4. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
5. Myc antagonizes Ras-mediated growth arrest in leukemia cells through the inhibition of the Ras-ERK-p21Cip1 pathway.
Vaqué JP; Navascues J; Shiio Y; Laiho M; Ajenjo N; Mauleon I; Matallanas D; Crespo P; León J
J Biol Chem; 2005 Jan; 280(2):1112-22. PubMed ID: 15528212
[TBL] [Abstract][Full Text] [Related]
6. Vitexin isolated from Prosopis cineraria leaves induce apoptosis in K-562 leukemia cells via inhibition of the BCR-ABL-Ras-Raf pathway.
Sarkar MK; Kar A; Jayaraman A; Kar Mahapatra S; Vadivel V
J Pharm Pharmacol; 2022 Jan; 74(1):103-111. PubMed ID: 34109977
[TBL] [Abstract][Full Text] [Related]
7. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
[TBL] [Abstract][Full Text] [Related]
8. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.
Amarante-Mendes GP; Naekyung Kim C; Liu L; Huang Y; Perkins CL; Green DR; Bhalla K
Blood; 1998 Mar; 91(5):1700-5. PubMed ID: 9473236
[TBL] [Abstract][Full Text] [Related]
9. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
10. BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells.
Mizuchi D; Kurosu T; Kida A; Jin ZH; Jin A; Arai A; Miura O
Biochem Biophys Res Commun; 2005 Jan; 326(3):645-51. PubMed ID: 15596148
[TBL] [Abstract][Full Text] [Related]
11. Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.
Zhang X; Jia D; Ao J; Liu H; Zang Y; Azam M; Habib SL; Li J; Ruan X; Jia H; Wang X; Li B
Oncotarget; 2016 Oct; 7(43):69945-69960. PubMed ID: 27564101
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
14. Reduction of Raf kinase inhibitor protein expression by Bcr-Abl contributes to chronic myelogenous leukemia proliferation.
Takemura T; Nakamura S; Yokota D; Hirano I; Ono T; Shigeno K; Fujisawa S; Ohnishi K
J Biol Chem; 2010 Feb; 285(9):6585-94. PubMed ID: 20028985
[TBL] [Abstract][Full Text] [Related]
15. Naturally Occurring Sesquiterpene Lactone-Santonin, Exerts Anticancer Effects in Multi-Drug Resistant Breast Cancer Cells by Inducing Mitochondrial Mediated Apoptosis, Caspase Activation, Cell Cycle Arrest, and by Targeting Ras/Raf/MEK/ERK Signaling Pathway.
Wu Z; Wang C; Huang M; Tao Z; Yan W; Du Y
Med Sci Monit; 2019 May; 25():3676-3682. PubMed ID: 31101800
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
Wen-Sheng W
Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
[TBL] [Abstract][Full Text] [Related]
17. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Packer LM; Rana S; Hayward R; O'Hare T; Eide CA; Rebocho A; Heidorn S; Zabriskie MS; Niculescu-Duvaz I; Druker BJ; Springer C; Marais R
Cancer Cell; 2011 Dec; 20(6):715-27. PubMed ID: 22169110
[TBL] [Abstract][Full Text] [Related]
18. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.
Morgan MA; Dolp O; Reuter CW
Blood; 2001 Mar; 97(6):1823-34. PubMed ID: 11238126
[TBL] [Abstract][Full Text] [Related]
19. The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells.
Pellicano F; Simara P; Sinclair A; Helgason GV; Copland M; Grant S; Holyoake TL
Leukemia; 2011 Jul; 25(7):1159-67. PubMed ID: 21483442
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
